Ohio State Navbar


John Byrd, MD, Receives the LLS Award

June 15, 2017

John C. Byrd, MD, a Distinguished University Professor at Ohio State, where he directs the Division of Hematology and co-leads the Leukemia Research Program at the OSUCCC – James, was named the most recent recipient of the Leukemia & Lymphoma Society’s (LLS) prestigious Return of the Child Award. According to the LLS, this national award was established in 1986 to honor an individual whose career has been dedicated to blood cancer research and whose leadership—nationally and internationally—within the oncology and biomedical communities has helped develop treatments for blood cancers and thereby improved survival rates. Dr. Byrd is an internationally known clinical and laboratory specialist in leukemia and other blood malignancies at Ohio State, where he is a professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences. He also holds the D. Warren Brown Designated Chair in Leukemia Research. His research accomplishments over the past decade relate to studies done between the laboratory and clinic with several therapeutic agents active in chronic lymphocytic leukemia (CLL) and in related leukemias and lymphomas. His work has shown that therapeutic agents such as rituximab, TRU-16, flavopiridol, dinaciclib and the B-cell receptor kinase inhibitors (GS1101 and ibrutinib) are effective against CLL. He also has been active in developing therapeutic antibodies and other targeted agents in his pursuit of non-toxic therapies for leukemia. In February 2014, the U.S. Food and Drug Administration expanded the approved use of the drug ibrutinib (Imbruvica®) to treat certain patients with chronic lymphocytic leukemia (CLL). Ibrutinib is the first drug designed to target a protein that is essential for CLL-cell survival and proliferation. Much of the clinical and basic-science research that led to FDA approval was performed by scientists at the OSUCCC – James, particularly by Dr. Byrd and several of his colleagues. The rest of the story

Michael Caligiuri, MD, begins AACR presidency today

April 04, 2017

Dear Colleagues, Greetings! I am proud to announce that Michael A. Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute (OSUCCC – James), has become president of the American Association for Cancer Research (AACR) for a one-year term that began this morning at the AACR annual meeting in Washington, D.C. Dr. Caligiuri is the first person from Ohio State ever to be elected as president of the AACR, which was founded in 1907 and ranks today as the world’s first and largest professional organization dedicated to advancing cancer research. As president, Dr. Caligiuri will work with the AACR’s board of directors and its more than 37,000 members from over 100 countries to further the AACR mission of preventing and curing cancer through research, education, communication and collaboration. Specifically, he will focus on cancer health disparities and the power of big data to transform cancer care. Dr. Caligiuri, who has spent the past year as AACR president-elect, is an internationally renowned cancer researcher, administrator and educator who has helped lead the OSUCCC – James to global prominence since he was recruited to Ohio State in 1997 as a professor of internal medicine and associate director for clinical research at the OSUCCC – James. He was named director of the OSUCCC in 2003 and also became CEO of The James in 2008. In addition, he holds the John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research. Please join me in congratulating him on becoming president of the AACR and in wishing him well as he works to advance its mission, which aligns directly with the OSUCCC – James vision of creating a cancer-free world. Sincerely, Jeff Walker, MBA Chief Operating Officer and Sr. Executive Director for Administration The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The rest of the story

Meet John Byrd: A beacon of hope for cancer patients

August 29, 2016

Dr. John Byrd is recognized internationally for his pioneering work in developing highly effective treatments for patients suffering from the most common form of leukemia. Byrd, director of Ohio State’s Division of Hematology, now holds Ohio State’s most prestigious award for select faculty members who have exceptional accomplishments in research, teaching and service. Byrd discusses the life-saving research occurring at Ohio State in this second installment of a three-part series highlighting 2016 Distinguished University Professors The rest of the story


May 05, 2016

Experts from the OSUCCC – James and outside institutions will speak at a free Workshop on Extracellular Vesicles in Cancer Biology from 8:30 a.m.-4:30 p.m. Friday, May 27, in L035 James (Wasserstrom Family Conference Room). Breakfast and lunch will be provided. View agenda Directors for the workshop are Ramiro Garzon, MD, associate professor in the Division of Hematology at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, and Muller Fabbri, MD, PhD, assistant professor in the Children's Center for Cancer and Blood Diseases at the University of Southern California. The workshop will enable scientists performing or planning to perform exosome and microvesicle research to meet, exchange ideas, discuss biological implications and future directions, and point out current problems and controversies in techniques, definitions and characterizations. Register The rest of the story

Byrd Chosen A Distinguished University Professor

May 04, 2016

The university has named John Byrd, MD, director of the Division of Hematology in the Department of Internal Medicine, a 2016 Distinguished University Professor. Dr. Byrd holds The D. Warren Brown Designated Chair in Leukemia Research. Distinguished University Professor is the highest honor the university bestows on a faculty member. To date, only 53 other faculty members have held the Distinguished University Professor title. The rest of the story

Ohio State's 2016 ASH Review Set for Jan. 22

December 08, 2015

Registration is open for Ohio State’s 2016 ASH Review, a Jan. 22 event that will provide a comprehensive overlook at advances in the biology, etiology, diagnosis, therapy and evidence-based management of blood cancers as presented at the 57th American Society of Hematology (ASH) Annual Meeting & Exposition held in December 2015 in Orlando, Fla. The ASH Review, to be held from 7:30 a.m.-3:30 p.m. in Room 115 of Ohio State’s Biomedical Research Tower, will include a presentation of the Michael R. Grever, MD, Distinguished Professor Lectureship by John C. Byrd, MD, professor and director of the Division of Hematology at Ohio State, and co-leader of the Leukemia Research Program at the OSUCCC – James. There is no fee to attend the review, and CME credit is available. Questions? Contact sarah.schmidt@osumc.edu or call 293-5521. The rest of the story

Immunology Seminar Program

November 10, 2015

NOV. 17 – Jianhua Yu, PhD, Associate Professor, Division of Hematology, Department of Internal Medicine at Ohio State, and Member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, “Understanding NK Cell Biology and Driving and Mobilizing Immune Cells to Kill Tumor Cells” The rest of the story

Caligiuri Delivers 'State of the Cancer Program Address'

November 10, 2015

OSUCCC – JAMES IS CHANGING THE LANDSCAPE OF CANCER CARE Continuing growth and advancement during the past year have bolstered Ohio State’s capacity for changing the landscape of cancer care and research in Ohio and around the globe, OSUCCC Director and James CEO Michael A. Caligiuri, MD, said Monday. Delivering his “State of the Cancer Program Address,” Caligiuri referenced “an amazing year” that included the opening of a new James Cancer Hospital and Solove Research Institute, and the attainment of a perfect score following a National Cancer Institute (NCI) five-year site review that led to a second consecutive “exceptional” rating for the OSUCCC – James, assuring its re-designation as a comprehensive cancer center. “If you take anything away from here today, it should be that we’ve had extraordinary growth and improvement in everything we do, and it’s making a profound difference to people who hear those three words, ‘You have cancer,’” Caligiuri told a standing-room-only audience in OSU’s Biomedical Research Tower. The rest of the story

John C. Byrd, MD Received the Hendrix College Odyssey Medal for Research

November 10, 2015

John C. Byrd, MD, professor and director of the Division of Hematology at Ohio State, where he also is co-leader of the Leukemia Research Program at the OSUCCC – James, received the Hendrix College Odyssey Medal for Research on Oct. 22 in Conway, Ark. Hendrix, a private liberal arts college where Byrd earned his undergraduate degree with distinction in chemistry in 1987, presents the Odyssey Medal each year to alumni “whose personal and professional achievements exemplify the values of engaged liberal arts and science education.” Byrd was among four recipients this year, and the only one for Research; the others were awarded for Special Projects or Service to the World. The college states that Byrd, who also holds the D. Warren Brown Designated Chair in Leukemia Research at Ohio State, is “a nationally known researcher and clinical specialist in leukemia and other hematologic malignancies” who has “been part of the development of multiple acute myeloid leukemia and chronic lymphocytic leukemia therapeutics.” The rest of the story

Study Rejects Biologic Age As Limiting Factor For Stem Cell Transplants

November 10, 2015

STUDY REJECTS BIOLOGIC AGE AS LIMITING FACTOR FOR STEM CELL TRANSPLANTS More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase II study led by oncologists at the OSUCCC – James. Steven Devine, MD, director of blood and marrow transplantation, led the study, which was published in the Journal of Clinical Oncology. The rest of the story